Ricolinostat

Drug Overview

Ricolinostat (also known as ACY-1215) is an innovative “Smart Drug” designed to treat specific blood cancers and solid tumors. It is a highly specialized Targeted Therapy that belongs to a class of medicines called HDAC inhibitors. Unlike older treatments that affect many different parts of a cell, ricolinostat is engineered to be “selective,” meaning it aims for a specific target while leaving other cellular processes alone.

In the corporate medical world, ricolinostat is recognized for its ability to disrupt the “waste disposal system” of cancer cells. For patients in the US, Europe, and international markets, this represents a major advancement in precision oncology. By making cancer cells unable to clean up their own cellular trash, the drug causes them to become overwhelmed and die, often working better when combined with other anti-cancer medications.

• Generic Name: Ricolinostat
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Selective Histone Deacetylase 6 (HDAC6) Inhibitor
• Route of Administration: Oral (Capsule)
• FDA Approval Status: Investigational (Currently in Phase I/II Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how ricolinostat works, imagine a cancer cell is a busy factory. This factory produces a lot of “trash” (toxic proteins). To stay alive, the factory uses a specialized disposal system called the aggresome pathway. Ricolinostat is like a lock that jams the door to the trash incinerator.

At the molecular level, the drug operates through a precise biological process:

1. Selective Targeting of HDAC6: Most HDAC inhibitors block many enzymes (HDAC 1 through 11). Ricolinostat specifically targets HDAC6. This selectivity is important because it reduces the harsh side effects often seen with non-selective drugs.
2. Disrupting Protein Degradation: HDAC6 is a key “manager” of the cell’s skeleton (microtubules) and the aggresome pathway. By blocking HDAC6, ricolinostat prevents the cell from gathering and destroying misfolded, toxic proteins.
3. Protein Overload: When ricolinostat is combined with other drugs (like proteasome inhibitors), the cancer cell’s two main trash disposal systems are both blocked. The toxic proteins build up until the cell becomes “clogged.”
4. Apoptosis (Programmed Cell Death): Once the protein stress becomes too high, the cell triggers its own self-destruct sequence, leading to the death of the tumor cell.
5. Immune Modulation: Recent research suggests that by blocking HDAC6, ricolinostat may also “unmask” the cancer cell, making it easier for the body’s natural immune system to find and attack it.

FDA-Approved Clinical Indications

As an investigational agent, ricolinostat is not yet approved by the FDA for general prescription. It is currently being utilized in strictly controlled clinical trials.

Oncological Uses (Investigational)

• Multiple Myeloma: Studied primarily in patients who have relapsed or have not responded to standard treatments.
• Lymphoma: Investigated for various types of non-Hodgkin lymphoma.
• Breast Cancer: Research into its effectiveness in hormone-receptor-positive advanced breast cancer.
• Solid Tumors: Early-stage trials for various aggressive solid tumors.

Non-Oncological Uses

• Diabetic Peripheral Neuropathy: Investigated for its ability to protect nerve cells from damage.

Dosage and Administration Protocols

Ricolinostat is taken as an oral capsule. Because it is in the trial phase, dosages are carefully adjusted by clinical researchers to find the best balance between safety and effectiveness.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: Since the liver processes ricolinostat, patients with liver issues are monitored with frequent blood tests. Doses may be reduced if liver enzymes rise.
• Renal (Kidney) Insufficiency: No specific adjustments are currently standard, but kidney filtration is tracked throughout the treatment cycles.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 have focused on how ricolinostat performs when “teamed up” with other medications.

• Multiple Myeloma Success: In Phase Ib/II trials (such as the ACY-1215-102 study), ricolinostat combined with pomalidomide and dexamethasone showed an Objective Response Rate (ORR) of approximately 29% to 35% in patients whose cancer was highly resistant to other drugs.
• Disease Control: Numerical data suggests that many patients achieved “Stable Disease,” meaning their cancer stopped growing for several months.
• Synergy with Chemotherapy: Recent studies (2024) indicate that ricolinostat may significantly increase the “killing power” of standard chemotherapy in breast cancer cells without adding significant toxicity.

Safety Profile and Side Effects

Black Box Warning:

None. (As an investigational drug, it has no formal Black Box Warning, but it is monitored for gastrointestinal and blood-related safety).

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired or weak.
• Diarrhea: Manageable stomach upset or loose stools.
• Nausea: A general feeling of sickness in the stomach.
• Neutropenia: A drop in infection-fighting white blood cells.
• Thrombocytopenia: A decrease in blood platelets (which help with clotting).

Serious Adverse Events

• Severe Cytopenia: Dangerously low blood counts that may require a treatment pause.
• Gastrointestinal Distress: Severe vomiting or diarrhea leading to dehydration.
• Hepatotoxicity: Temporary stress on the liver (seen in blood tests).

Management Strategies

• Blood Monitoring: Patients must have their blood counts checked weekly during the start of treatment.
• Dose Interruptions: If white blood cells or platelets drop too low, the drug is paused until the levels return to a safe range.

Research Areas

In the fields of Immunotherapy and Regenerative Medicine, ricolinostat is a major topic of interest. Scientists are investigating if ricolinostat can act as an “Immune Primer.” By blocking HDAC6, the drug may help the body’s T-cells become more effective at recognizing cancer. Current research (2025) is testing ricolinostat alongside Checkpoint Inhibitors to see if this combination can help the immune system “regenerate” a long-term defense against tumors that were previously hidden.

Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Complete Blood Count (CBC): To ensure blood levels are safe before starting.
• Liver Function Tests (LFTs): To establish a baseline for liver health.
• Comprehensive Metabolic Panel (CMP).

Precautions During Treatment

• Infection Prevention: Because white blood cells may drop, avoid crowds and wash hands frequently.
• Hydration: Drink plenty of fluids to prevent dehydration if mild diarrhea occurs.

“Do’s and Don’ts” List

• Do take your medication exactly as prescribed by your clinical trial team.
• Do report any sudden fever, chills, or unusual bruising immediately.
• Don’t skip your scheduled blood tests; they are vital for your safety.
• Don’t take any new over-the-counter supplements without asking your oncologist first.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Ricolinostat is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss your specific diagnosis, treatment options, and potential risks. This content reflects research data available as of early 2026.